New data reveal molecular drivers of TED may remain activated in patients with low Clinical Activity Score
New details define the molecular patterns in thyroid eye disease and further implicate the role of insulin-like growth factor-1 in patients with low Clinical Activity Scores.
EYP-1901: A look at DAVIO and PAVIA clinical trial updates
Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.
Verana Health + AAO IRIS Registry joint initiative yields 3.5 million ophthalmic images
Lawrence Whittle, Chief Commercial Officer for Verana Health, explains what the significance of imaging data linked with electronic health record data means for patient outcomes.
Promising results for faricimab revealed in TENAYA, LUCERNE year 2 data
Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.
Verana Research Network set sights on better access to clinical care
Marc Berger, Chief Operating Officer at Verana Health, highlights what a new initiative with the American Academy of Ophthalmology IRIS Registry will mean for patients and physicians.
Centricity Vision’s new ZEPTO Plus handpiece gives surgeons a choice in capsulotomy size
CEO Rob Thornhill discusses the features of the device, as well as plans for a new technology called ZEPTOLINK which combines the company’s novel ZEPTO technology with any phaco device.
Portable laser technology receives high marks
Harit Bhatt, MD, a Chicagoland-area retinal surgeon, shared his experience with the LEAF and LION portable lasers during a conversation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago.
Zeroing in on vision-threatening causes of diplopia
Vivek Patel, MD, discusses issues that could threaten sight during presentation at the American Academy of Ophthalmology annual meeting in Chicago.
Harvesting limbal stem cells from healthy eyes to treat corneal blindness
Ula V. Jurkunas, MD, discusses a presentation she gave recently at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago on the use of limbal stem cells to treat corneal blindness.
Aerie continues COMET program to study treatment of dry eye
Michelle Senchyna, PhD, provided an update of the COMET program and other development activities at Aerie Pharmaceuticals during a conversation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago.
Update on TENAYA and LUCERENE clinical trials
During a conversation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Rishi Singh, MD, offered highlights of the two-year results of faricimab in a pair of phase 3 clinical trials.
ARMOR study can offer starting point for treatment of patients with serious eye infections, corneal ulcers
According to Penny Asbell, MD, FACS, MBA, the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study has identified high levels of in vitro antibiotic resistance among ocular staphylococcal and pneumococcal pathogens, resistance that may affect treatment success. She discussed the program at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago.
New optics textbook aims to be a compendium resource for the topic
At AAO, Kamran Riaz, MD, discussed the new textbook, "Optics for the New Millennium," which is intended to be a compendium resource for ophthalmologists.
Adaptive cataract surgery system streamlines procedure
Harvey Uy, MD, has been using the Ally adaptive cataract treatment system at his clinic in the Philippines, and it is allowing him to be more efficient.
Real World Ophthalmology networking offers early-practice career advice
Lisa M. Nijm, MD, JD, shares highlights from the Real World Ophthalmology 'After Dark' networking reception held at the American Academy of Ophthalmology annual meeting. The next Real World Ophthalmology meeting on November 5—which will be virtual—will cover important clinical, business, and personal growth areas for young ophthalmologists.
Moving beyond the drop: CEO provides updates on Oyster Point's pipeline
Jeff Nau, PhD, MMS, President and CEO of Oyster Point Pharmaceuticals, provides an appraisal of the company's pipeline as well as updates on recent innovations to hit the market.
Using these 2 acronyms daily in your ophthalmic practice can deliver good service
Mike Lyons, PHR, MHRIR, and Megan Odell, BHA, MHHR, with Austin Retina Associates, outline how to implement the GREAT and the LEAP method for an improved employee and patient experience.
FDA grants clearance for amblyopia treatment device
NovaSight’s CureSight is a digital device that proved in a pivotal study to be non-inferior to patching, according to the company.
ViaLase seeks to disrupt glaucoma treatment paradigm with new femtosecond laser treatment
Shawn O'Neil of ViaLase shares updates on the company's femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) treatment.
Contralateral eye study investigates iStent vs Hydrus stent for glaucoma
At AAO 2022, Mitch Shultz, MD, provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.
Trukera Medical rebranding allows team to expand into the broader corneal health market
Adam Szaronos, President and CEO of Trukera Medical, discusses the recent rebranding of TearLab as well as the launch of the ScoutPro Osmolarity System.
Dr Donny Suh: Finding purpose and passion for ophthalmology
Donny W. Suh, MD, finds his love for practicing pediatric ophthalmology grows stronger with each passing year. He offers two tips to fellow physicians and his residents and fellows for managing the stressors of daily practice and for getting a good night’s sleep. He also shares his journey in a book called “Catching A Star,” with all proceeds going to a medical mission program.
How to express your passion through innovation: pearls for young ophthalmologists
Murtaza Adam, MD, a vitreoretinal specialist with Colorado Retina Associates, shares a few principles he has found helpful when engaging with industry or trying to execute on your own innovation.
Assessing the effectiveness of netarsudil and episcleral blood flow in treatment-naive glaucoma suspects, hypertension subject
Osamah Saeedi, MD, MS, discusses his AAO 2022 talk titled, "Single-Cell Erythrocyte Tracking in Human Subjects Reveals Increase in Episcleral Venous Flow With Netarsudil 0.02%."
AAO LIVE: Researchers target risk factors for development of rhegmatogenous retinal detachments
In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, William Kearney and Dan Gong, MD, discussed how patients with a unilateral retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.
More ocular symptoms found in smokers who used cigarettes than e-cigarettes
Those who used both traditional and electronic cigarettes reported severe to very severe ophthalmic symptoms.
COVID-19-imposed health care restrictions had no negative effects on status of DME
DME showed small significant improvement in study cohort.
Pooled Phase 3 data reports safety, efficacy, reduced treatment burden with faricimab compared with aflibercept for the treatment of nAMD
The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability, and safety of faricimab in patients with neovascular AMD.
Higher rates of repeat corneal crosslinking need found in younger patients
At AAO 2022, Philip Dockery, MD, MPH, presents, "Effectiveness of corneal crosslinking in young patients."
Robot-assisted micro interventional glaucoma surgery reduces surgeon's tremors
Gautam Kamthan, MD, presented data at AAO 2022 regarding robot-assisted micro interventional glaucoma surgery.
2 Clarke Drive Cranbury, NJ 08512